Cisplatin is one of the most widely used anticancer drugs in the treatment of various types of solid human cancers, as well as germ cell tumors, sarcomas, and lymphomas. Strong evidence from research has demonstrated higher efficacy of a combination of cisplatin and derivatives, together with hyperthermia and light, in overcoming drug resistance and improving tumoricidal efficacy. It is well known that the antioncogenic potential of CDDP is markedly enhanced by hyperthermia compared to drug treatment alone. However, more recently, accelerators of high energy particles, such as synchrotrons, have been used to produce powerful and monochromatizable radiation to induce an Auger electron cascade in cis-platinum molecules. This is the concept that makes photoactivation of cis-platinum theoretically possible. Both heat and light increase cisplatin anticancer activity via multiple mechanisms, generating DNA lesions by interacting with purine bases in DNA followed by activation of several signal transduction pathways which finally lead to apoptosis. For the past twenty-seven years, our group has developed infrared photo-thermal activation of cisplatin for cancer treatment from bench to bedside. The future development of photoactivatable prodrugs of platinum-based agents injected intratumorally will increase selectivity, lower toxicity and increase efficacy of this important class of antitumor drugs, particularly when treating tumors accessible to laser-based fiber-optic devices, as in head and neck cancer. In this article, the mechanistic rationale of combined intratumor injections of cisplatin and laser-induced thermal therapy (CDDP–LITT) and the clinical application of such minimally invasive treatment for cancer are reviewed.
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, including in the United States. Risk factors such as high cholesterol, diabetes, obesity, smoking, physical inactivity, and hypertension contribute significantly to their development. Emerging evidence highlights a central role for chemokines—small signaling molecules that guide immune cell migration to sites of infection, inflammation, or tissue damage—in the initiation and progression of hypertension. This positions chemokines and their receptors as promising pharmacological targets for blood pressure regulation and vascular protection. In this review, we explore the therapeutic potential of targeting chemokines and their receptors and summarize the main strategies reported in the literature for managing hypertension through these pathways. For this purpose, an analysis of drugs that act on the most relevant receptors at the preclinical and clinical levels was performed. After this analysis, their mechanisms of action, selectivity, and possible adverse effects were discussed. In conclusion, we reinforce that the modulation of chemokines and their receptors represents a promising approach in the control of CVDs, especially hypertension, although further clinical studies are needed to validate the efficacy and safety of this strategy, considering possible impacts on other essential immune responses.